Black Diamond Therapeutic Analyst Ratings
Black Diamond Therapeutic Analyst Ratings
While ratings are subjective and will change, the latest Black Diamond Therapeutic (BDTX) rating was a reiterated with a price target of $0.00 to $11.00. The current price Black Diamond Therapeutic (BDTX) is trading at is $2.15, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/22/2023 | 411.63% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
| 09/12/2023 | 365.12% | Wedbush | → $10 | Reiterates | Outperform → Outperform |
| 07/14/2023 | 411.63% | Piper Sandler | → $11 | Initiates Coverage On | → Overweight |
| 06/30/2023 | 365.12% | Stifel | $2 → $10 | Upgrades | Hold → Buy |
| 06/28/2023 | 411.63% | HC Wainwright & Co. | → $11 | Upgrades | Neutral → Buy |
| 06/27/2023 | -6.98% | Stifel | → $2 | Reiterates | Hold → Hold |
| 06/27/2023 | 365.12% | Wedbush | $3 → $10 | Upgrades | Neutral → Outperform |
| 05/10/2023 | 39.53% | Wedbush | → $3 | Reiterates | → Neutral |
| 03/29/2022 | — | Wedbush | Downgrades | Outperform → Neutral | |
| 03/22/2022 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 03/18/2022 | 86.05% | Stifel | $10 → $4 | Maintains | Hold |
| 09/30/2021 | 365.12% | Stifel | → $10 | Initiates Coverage On | → Hold |
| 01/07/2021 | — | Wedbush | Initiates Coverage On | → Outperform | |
| 11/24/2020 | 2597.67% | Berenberg | → $58 | Initiates Coverage On | → Buy |
| 05/04/2020 | 2365.12% | HC Wainwright & Co. | → $53 | Initiates Coverage On | → Buy |
| 02/24/2020 | 2086.05% | Jefferies | → $47 | Initiates Coverage On | → Buy |
| 02/24/2020 | 2225.58% | Canaccord Genuity | → $50 | Initiates Coverage On | → Buy |
| 02/24/2020 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 02/24/2020 | 1853.49% | JP Morgan | → $42 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/22/2023 | 411.63% | HC Wainwright & Co. | → 11 美元 | 重申 | 购买 → 购买 |
| 09/12/2023 | 365.12% | Wedbush | → 10 美元 | 重申 | 跑赢大盘 → 跑赢大盘 |
| 07/14/2023 | 411.63% | 派珀·桑德勒 | → 11 美元 | 启动覆盖范围开启 | → 超重 |
| 06/30/2023 | 365.12% | Stifel | 2 美元 → 10 美元 | 升级 | 持有 → 买入 |
| 06/28/2023 | 411.63% | HC Wainwright & Co. | → 11 美元 | 升级 | 中性 → 买入 |
| 06/27/2023 | -6.98% | Stifel | → 2 美元 | 重申 | 按住 → 按住 |
| 06/27/2023 | 365.12% | Wedbush | 3 美元 → 10 美元 | 升级 | 中性 → 跑赢大盘 |
| 05/10/2023 | 39.53% | Wedbush | → 3 美元 | 重申 | → 中立 |
| 03/29/2022 | — | Wedbush | 降级 | 跑赢大盘 → 中性 | |
| 03/22/2022 | — | HC Wainwright & Co. | 降级 | 买入 → 中性 | |
| 03/18/2022 | 86.05% | Stifel | 10 美元 → 4 美元 | 维护 | 保持 |
| 09/30/2021 | 365.12% | Stifel | → 10 美元 | 启动覆盖范围开启 | → 按住 |
| 01/07/2021 | — | Wedbush | 启动覆盖范围开启 | → 跑赢大盘 | |
| 11/24/2020 | 2597.67% | 贝伦贝格 | → 58 美元 | 启动覆盖范围开启 | → 购买 |
| 05/04/2020 | 2365.12% | HC Wainwright & Co. | → 53 美元 | 启动覆盖范围开启 | → 购买 |
| 2020 年 2 月 24 日 | 2086.05% | 杰富瑞集团 | → 47 美元 | 启动覆盖范围开启 | → 购买 |
| 2020 年 2 月 24 日 | 2225.58% | Canaccord Genu | → 50 美元 | 启动覆盖范围开启 | → 购买 |
| 2020 年 2 月 24 日 | — | Cowen & Co. | 启动覆盖范围开启 | → 跑赢大盘 | |
| 2020 年 2 月 24 日 | 1853.49% | 摩根大通 | → 42 美元 | 启动覆盖范围开启 | → 超重 |
What is the target price for Black Diamond Therapeutic (BDTX)?
黑钻疗法（BDTX）的目标价格是多少？
The latest price target for Black Diamond Therapeutic (NASDAQ: BDTX) was reported by HC Wainwright & Co. on November 22, 2023. The analyst firm set a price target for $11.00 expecting BDTX to rise to within 12 months (a possible 411.63% upside). 8 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年11月22日公布了黑钻疗法（纳斯达克股票代码：BDTX）的最新目标股价。该分析公司将目标股价定为11.00美元，预计BDTX将在12个月内升至12个月内（可能上涨411.63％）。去年有8家分析公司公布了评级。
What is the most recent analyst rating for Black Diamond Therapeutic (BDTX)?
分析师对黑钻疗法（BDTX）的最新评级是多少？
The latest analyst rating for Black Diamond Therapeutic (NASDAQ: BDTX) was provided by HC Wainwright & Co., and Black Diamond Therapeutic reiterated their buy rating.
HC Wainwright & Co. 对黑钻疗法（纳斯达克股票代码：BDTX）的最新分析师评级由HC Wainwright & Co. 提供，黑钻治疗重申了其买入评级。
When is the next analyst rating going to be posted or updated for Black Diamond Therapeutic (BDTX)?
下一次分析师对黑钻疗法（BDTX）的评级将在何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Black Diamond Therapeutic, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Black Diamond Therapeutic was filed on November 22, 2023 so you should expect the next rating to be made available sometime around November 22, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Black Diamond Therapical的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。黑钻疗法的最新评级是在2023年11月22日公布的，因此您应该预计下一个评级将在2024年11月22日左右公布。
Is the Analyst Rating Black Diamond Therapeutic (BDTX) correct?
分析师对黑钻疗法（BDTX）的评级是否正确？
While ratings are subjective and will change, the latest Black Diamond Therapeutic (BDTX) rating was a reiterated with a price target of $0.00 to $11.00. The current price Black Diamond Therapeutic (BDTX) is trading at is $2.15, which is within the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的黑钻疗法（BDTX）评级得到了重申，目标股价为0.00美元至11.00美元。黑钻疗法（BDTX）的当前交易价格为2.15美元，在分析师的预测区间内。
